more interest in "abuse-deterrent" opioid formulations
The Zohydro controversy will lead to more interest in "abuse-deterrent" opioid formulations.
Zohydro is the new long-acting hydrocodone for chronic, severe pain. It's controversial because it's NOT an abuse-deterrent formulation...despite concerns about its abuse potential.
Abuse-deterrent formulations aren't required by FDA...but are being promoted in an effort to reduce prescription opioid abuse.